# Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

> **NCT00069238** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Lymphoma, T-Cell
- Lymphoma, Extranodal NK-T-Cell

## Interventions

- **BIOLOGICAL:** Alemtuzumab (Campath)
- **DRUG:** EPOCH

## Key facts

- **NCT ID:** NCT00069238
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09-19
- **Primary completion:** 2009-06-11
- **Final completion:** 2021-03-17
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00069238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00069238, "Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00069238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*